Functional Endoscopic Sinus Surgery (FESS) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Functional Endoscopic Sinus Surgery (FESS) is a minimally invasive surgical technique used to treat chronic sinusitis and other sinonasal disorders that have not responded to medical therapy. The procedure uses a rigid nasal endoscope — a thin, illuminated telescope — inserted through the nostrils to visualise the sinus openings and drainage pathways with exceptional clarity, without any external incisions. The surgeon removes diseased tissue, polyps, and bony obstructions that block natural sinus drainage, restoring normal mucociliary clearance and ventilation.

Unlike traditional open sinus operations, FESS preserves the normal sinonasal anatomy and leaves surrounding structures intact. Powered microdebriders, balloon sinuplasty catheters, and image-guided navigation systems are commonly employed to maximise precision and minimise collateral tissue damage. The procedure is typically performed under general anaesthesia as a day-case or overnight admission, lasting between 60 and 180 minutes depending on the number of sinuses involved.

Chronic rhinosinusitis affects approximately 11% of adults worldwide, causing significant morbidity through facial pain, nasal congestion, hyposmia, and reduced quality of life. FESS is considered the gold-standard surgical option when at least 12 weeks of optimised medical treatment — including intranasal corticosteroids and antibiotics — has failed to control symptoms. Pre-operative computed tomography (CT) of the sinuses is mandatory to map anatomy and identify disease extent before surgery is undertaken.

FESS is the primary surgical treatment for chronic rhinosinusitis with or without nasal polyps (CRSwNP and CRSsNP). It is particularly effective in patients with eosinophilic polyp disease, fungal sinusitis (allergic fungal rhinosinusitis and fungus ball), and mucoceles — mucus-filled cysts that expand into adjacent structures including the orbit and skull base.

Additional indications include recurrent acute rhinosinusitis (four or more acute episodes per year), antrochoanal polyps, inverted papilloma with low malignant potential, benign sinonasal tumours, cerebrospinal fluid (CSF) rhinorrhoea repair, orbital decompression for thyroid eye disease, dacryocystorhinostomy (DCR) for nasolacrimal duct obstruction, and trans-sphenoidal access for pituitary gland surgery. Septoplasty and inferior turbinate reduction are frequently performed at the same sitting to improve the overall nasal airway. Patients are selected for this procedure following thorough clinical assessment, diagnostic imaging, and where applicable pathological confirmation, ensuring that each case meets the evidence-based indications supported by current international clinical practice guidelines.

Ideal candidates for FESS are adults and older adolescents with CT-confirmed chronic sinusitis whose symptoms — nasal congestion, facial pressure, mucopurulent discharge, and hyposmia — persist despite at least 12 weeks of maximal medical therapy including nasal saline irrigation, intranasal corticosteroids, and, where indicated, a course of oral antibiotics or a short course of systemic steroids. Patients with nasal polyp disease causing significant olfactory loss or bronchial asthma exacerbations are particularly likely to benefit. Allergy evaluation and optimisation of asthma control should precede surgery where relevant.

FESS is relatively contraindicated in patients with bleeding diatheses (INR >1.5 or platelet count <50,000) that cannot be corrected, uncontrolled hypertension, or those who cannot tolerate general anaesthesia. Patients on aspirin, clopidogrel, or anticoagulants require a structured peri-operative bridging plan in liaison with their cardiologist or haematologist. Children under 10 are generally offered conservative management first, as aggressive surgery may interfere with mid-face growth. Extensive skull base erosion from malignant disease warrants craniofacial rather than endoscopic-only resection.

Standard FESS involves uncinectomy (removal of the uncinate process), maxillary antrostomy, anterior and posterior ethmoidectomy, sphenoidotomy, and frontal sinusotomy as dictated by disease extent. The Messerklinger technique (anterior-to-posterior approach) is the most widely practised; the Wigand technique (posterior-to-anterior) is preferred by some surgeons for extensive disease. Powered microdebrider-assisted FESS reduces soft-tissue bleeding and speeds tissue removal compared to purely cold-steel dissection.

Balloon catheter sinuplasty (BCS) is a less-invasive variant in which a guide catheter and balloon are used to dilate the natural ostia of the maxillary, frontal, and sphenoid sinuses without tissue removal. It is suitable for patients with ostial stenosis but minimal polypoid or fungal disease. Image-guided surgery (IGS) using electromagnetic or optical tracking linked to pre-operative CT significantly reduces the risk of orbital and skull-base injuries in revision cases or complex anatomy. Hybrid procedures combining balloon dilation for the frontal and sphenoid with conventional endoscopic ethmoidectomy are increasingly popular for moderate disease. Revision FESS for recurrent disease may require CT-guided navigation and intra-operative steroid irrigation protocols. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options.

FESS achieves symptom improvement in 85–90% of appropriately selected patients with chronic rhinosinusitis. Large multicentre studies, including the CAMS-2 trial, demonstrate that surgery plus medical therapy provides superior quality-of-life outcomes compared to medical therapy alone at 12 months. Patients typically experience significant improvement in nasal airflow, facial pain, sense of smell, and sleep quality within four to six weeks of surgery. Nasal polyp recurrence rates at five years range from 30% in non-eosinophilic disease to 50–70% in aspirin-exacerbated respiratory disease; adjunct biologics such as dupilumab can substantially reduce recurrence post-operatively.

FESS markedly reduces the frequency and severity of acute exacerbations and antibiotic courses required, lowering the long-term burden on patients with comorbid asthma, cystic fibrosis, or primary ciliary dyskinesia. Short-term outcomes include minimal visible scarring (no external incisions), shorter hospital stay (usually day-case or one night), rapid return to work (5–7 days for office work), and a low rate of serious complications (<1% in experienced centres). Patient-reported outcome measures using validated tools such as the SNOT-22 score demonstrate sustained improvements of 20–40 points over baseline at 12–24 months.

Common minor complications after FESS include post-operative epistaxis (5–10%), temporary crusting and nasal discharge requiring saline irrigation for 4–6 weeks, synechia (adhesion) formation between opposing mucosal surfaces (5–10%), and transient facial numbness from infraorbital nerve traction. Some patients experience temporary worsening of smell during the healing phase. Periorbital bruising and swelling are common within the first 48 hours, particularly after ethmoidectomy near the medial orbital wall (lamina papyracea).

Serious but rare complications occur in approximately 0.5–1% of cases. Orbital injury — ranging from medial rectus muscle damage causing diplopia to retrobulbar haematoma causing vision loss — is the most feared, occurring in <0.1% of cases at high-volume centres. Inadvertent opening of the cribriform plate or skull base may result in CSF leak and meningitis; intra-operative identification with fluorescein and immediate repair minimises sequelae. Major arterial injury (anterior ethmoid artery or internal carotid artery in the sphenoid) is extremely rare (<0.05%) but potentially life-threatening. Recurrence of polypoid disease necessitating revision surgery is not technically a complication but is a realistic long-term expectation in eosinophilic disease.

The immediate post-operative period involves nasal packing (if used) removal within 24–48 hours, followed by daily hypertonic saline irrigation (2–3 times daily) beginning on day two and continuing for a minimum of 12 weeks. Patients are reviewed in clinic at 1–2 weeks for endoscopic debridement of crusting and blood clots, which is critical to prevent synechia and optimise healing. Further clinic reviews at four to six weeks assess the patency of the surgically opened sinuses and remove any residual adhesions under topical anaesthesia.

Activity restrictions include avoidance of strenuous exercise and nose blowing for two weeks, avoidance of swimming or diving for four weeks, and avoidance of contact sports for six weeks. Intranasal corticosteroid sprays are resumed as soon as comfortable (usually day three to five) and continued indefinitely as long-term maintenance therapy. Patients with polyp disease are counselled regarding dietary triggers (aspirin-exacerbated respiratory disease, salicylates), encouraged to maintain adherence to topical corticosteroid therapy, and may require biologic therapy (dupilumab, mepolizumab) if disease is severe or recurrent. Annual endoscopic surveillance is recommended for the first three years.

FESS costs in the United States range from USD 8,000 to USD 20,000 depending on the number of sinuses operated, use of image guidance, and whether balloon sinuplasty devices are employed. In the United Kingdom, private FESS typically costs GBP 4,000 to GBP 8,000. These figures include anaesthesia, theatre, and a single post-operative review but may exclude intra-operative navigation costs (typically USD 500–1,500 per case in the US). Insurance coverage is variable and frequently requires prior authorisation and documented failure of medical therapy for a defined duration.

Patients seeking quality care at reduced cost can access FESS at JCI-accredited hospitals in India (USD 1,500–3,500), Thailand (USD 2,500–5,000), Turkey (USD 1,800–4,000), and Mexico (USD 2,000–4,500). Indian tertiary ENT centres such as AIIMS Delhi, Medanta, and Apollo Hospitals offer image-guided FESS by fellowship-trained rhinologists at a fraction of Western costs, achieving 60–80% savings. Medical tourism packages typically include pre-operative CT evaluation, the surgical procedure, overnight hospitalisation, post-operative endoscopic debridement, and a structured saline irrigation protocol, allowing international patients to complete the critical early healing period before return travel.

Medical management remains the first-line approach for chronic rhinosinusitis and includes intranasal corticosteroid sprays, saline irrigation, targeted antibiotic therapy for acute exacerbations, and systemic corticosteroids for severe polypoid disease. Leukotriene receptor antagonists (montelukast) may help patients with aspirin sensitivity. Biological therapies — dupilumab (anti-IL-4/IL-13), mepolizumab (anti-IL-5), and omalizumab (anti-IgE) — are transforming management of severe eosinophilic polyp disease and may delay or reduce the need for surgery; they are however expensive and require ongoing administration.

For patients with predominantly ostial stenosis and limited polypoid disease, in-office balloon sinuplasty under local anaesthesia offers a less invasive option with faster recovery and lower cost. Traditional external approaches (Caldwell-Luc for maxillary sinus, Lynch for frontal sinus) are now rarely performed, reserved for special circumstances such as extensive benign or malignant sinonasal tumours where endoscopic resection margins cannot be confirmed. Saline irrigation alone and antihistamines for allergic rhinitis may be sufficient for mild or seasonal disease that does not progress to chronic sinusitis.